All In Biotech

Drug Trial Radar · NCT05170841

Study Evaluating Dexketoprofen Trometamol/Tramadol Hydrochloride Analgesic Efficacy in Acute Low Back Pain

Randomized, Double-blind, Placebo-controlled, Parallel Arm Group Study Evaluating Analgesic Efficacy and Safety of Dexketoprofen Trometamol and Tramadol Hydrochloride on Moderate to Severe Acute Pain in Patients With Acute Low Back Pain

Last checked: Nov 20, 2026Latest source record: Jan 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 538 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

538

Actual

Start

Sep 17, 2020

Primary completion

May 4, 2022

Study completion May 4, 2022

Sponsor

Sponsor type
Industry
First posted
Dec 28, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A randomized, double-blind, study to evaluate the analgesic efficacy and safety of Dexketoprofen trometamol and Tramadol hydrochloride combination versus placebo on moderate to severe acute pain in patients with acute low back pain.

Conditions

  • Low Back Pain

Interventions

  • Dexketoprofen Trometamol 25 mg/Tramadol Hydrochloride 75 mgDrug

    Administered as one single tablet to be taken every 8 hours

  • Tramadol Hydrochloride 100 mgDrug

    Administered as two capsules with 50 mg each to be taken every 8 hours

  • PlaceboDrug

    Administered as one tablet if matching Dexketoprofen Trometamol 25 mg and Tramadol Hydrochloride 75 mg or two capsules if matching Tramadol Hydrochloride 100 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to First Achieve a Numeric Rating Scale-Pain Intensity Score <4 or a Pain Intensity Reduction of ≥30% From Drug Intake Till 8 Hours After the First DoseTime frame: 8 hours from first intake (referring to first 8 hours of Single Dose Phase)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • University of L'Aquila

    L’Aquila, Italy

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.